Skip to content
The BCI Briefing

Company profileCore BCI

Precision Neuroscience

A thin-film cortical surface array that slides under the skull through a narrow slit.

Location
New York, United States
Founded
2021
Class
Core BCI
Website
precisionneuro.io
Funding stage
Series D
Sources last checked
3 Oct 2026

What they are building

Builds the Layer 7 Cortical Interface, a 1,024-electrode film that records from and stimulates the cortical surface without penetrating it.

Interface category
Electrocorticography
Signal
Local field potentials, including high-gamma activity
Invasiveness
Minimally invasive
Recording / stimulation
Recording and stimulation
Device
Layer 7 Cortical Interface — Thin-film micro-ECoG array delivered through a slit in the skull
Channels
1,024 electrodes
Regulatory status
FDA-cleared for up to 30 days of use; chronic BCI use investigational
Main use cases
Control, Communicate

Where they are clinically

Approved / cleared

Authorised by a regulator for a defined use. Always check the scope.

FDA clearance covers temporary use of up to 30 days. Long-term use as a BCI remains investigational.

Access today

Clinical study

Accessible only by enrolling in a registered clinical study.

Shown in people
Recording and stimulation through a 1,024-electrode film during surgery in five patients, peer reviewed, and an FDA clearance for implantation of up to 30 days.
Still an aim
A permanently implanted BCI for control and communication. No chronic human data are public.
What stands in the way
Duration: showing that a surface film keeps its signal for months, and having the cleared 30 days extended.

On record here: 1 peer-reviewed paper

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

  • Apr 2025US FDA — 510(k) clearance. Temporary use of up to 30 days. Long-term implantation as a BCI is not covered.

Why this company matters

Precision holds the only FDA marketing clearance among high-channel cortical interfaces, but for a narrow, temporary indication. The strategic bet is that a reversible surface array can reach clinical usefulness sooner than penetrating electrodes, and that regulators will extend duration step by step. Chronic performance data in people are the evidence to watch.

Key milestones

  1. 25 Sep 2026

    $250M Series D led by Pershing Square and the Ackman Oxman Institute; total funding reaches $430M.

    MedTech Dive

  2. 2 Oct 2025

    Peer-reviewed description of the 1,024-channel array, slit-based delivery and a five-patient intraoperative pilot.

    Hettick M et al., Nature Biomedical Engineering

  3. Apr 2025

    FDA clearance for use of the Layer 7 Cortical Interface for up to 30 days.

    MedTech Dive

  4. Dec 2024

    Series C of $102M reported.

    pharmaphorum

Research

Funding history

  • 25 Sep 2026$250MSeries D · led by Pershing Square, Ackman Oxman InstituteBrings total funding to $430M. A life-sciences fund also co-led but was not named.
  • Dec 2024$102MSeries C · led by General Equity Holdings

Investors namedPershing Square · Ackman Oxman Institute · General Equity Holdings · B Capital

Rounds in the Briefing’s sample only; not a complete funding history.

Leadership

  • Michael Mager

    Co-founder and CEO

  • Benjamin Rapoport

    Co-founder and Chief Science Officer

As publicly stated by the organisation. Not a complete list.

IP and patents

Filings spread across 7 of the 11 layers, most often interface and electrodes (23 of 28 families) and stimulation (11).

28
patent families identified and counted as BCI
2016
earliest first filing among them
25
first filed since 2021; the latest years are incomplete
8 of 28
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: electrodes and arrays (23), stimulation (11), neural decoding (8), signal processing (6), closed loop (6), surgical planning and procedure (4). A family can carry several.

Published in: United States (26), Australia (12), Canada (4), China (1), Japan (1), counted over the 28 families whose full record was read.

Representative families

22 more families counted

Families found for Precision Neuroscience in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Latest BCI Briefing coverage

Sources

  1. 01

    Precision Neuroscience raises $250M for brain-computer interface work (opens in a new tab)

    Independent reportingMedTech Dive25 Sep 2026Checked against source 3 Oct 2026

  2. 02

    Neuralink rival Precision raises $102m, and other financings (opens in a new tab)

    Independent reportingpharmaphorumSource identified, not opened

    Amount confirmed from the headline; investor list not re-checked.

  3. 03

    Hettick M et al. Nat Biomed Eng 2026;10(6):1206–1221 (opens in a new tab)

    Peer reviewedNature Biomedical Engineering2 Oct 2025Checked against source 3 Oct 2026

    DOI 10.1038/s41551-025-01501-w